The Smart Drug Delivery of Rotigotine Using Transdermal Patch for the Successful Management of Parkinson's Disease.

Central nervous system agents in medicinal chemistry Pub Date : 2024-06-21 DOI:10.2174/0118715249289689240607064642

Jose Prakash Dharmian, Angelin Claret Seraphim PushpaNathan, Prakash Ramakrishnan, Raja Navamani Subramanian, Jayachandran David Levy, Pavazhaviji Palani, Venkateshwaran Krishnaswami

{"title":"The Smart Drug Delivery of Rotigotine Using Transdermal Patch for the Successful Management of Parkinson's Disease.","authors":"Jose Prakash Dharmian, Angelin Claret Seraphim PushpaNathan, Prakash Ramakrishnan, Raja Navamani Subramanian, Jayachandran David Levy, Pavazhaviji Palani, Venkateshwaran Krishnaswami","doi":"10.2174/0118715249289689240607064642","DOIUrl":null,"url":null,"abstract":"Background: A Non-Ergot Dopamine Agonist (NEDA) rotigotine has been designed as a new transdermal drug delivery system.Aim: To maintain optimum homogeneity in drug content, the rotigotine transdermal patch was developed utilizing a solvent casting technique.Methods: The characteristics of a transdermal patch, including patch weight, folding endurance, patch thickness, surface morphology, tensile strength, swelling rate, surface pH, in vitro release studies, water retention rate, uniformity of drug content, and ex-vivo permeation studies, were determined.Results: In vitro drug release studies unequivocally demonstrated that drug release controlled polymer interactions. There was no apparent lag period before the drug release rate started to decline. The developed patch showed 70 ± 1.18 % of prolongation of drug release within 24 hours. The result of the penetration studies demonstrated that 61 ± 2.52% of rotigotine permeated through the epidermal barrier within 24 h.Conclusion: The developed transdermal patch comprising rotigotine was evidently placed on the dermis layer, and an appropriate dose was delivered into circulation for a longer time based on the aforementioned factors. The findings of this study illustrate the effective approach of transdermal patches to treat Parkinson's disease.","PeriodicalId":93930,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central nervous system agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715249289689240607064642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: A Non-Ergot Dopamine Agonist (NEDA) rotigotine has been designed as a new transdermal drug delivery system.

Aim: To maintain optimum homogeneity in drug content, the rotigotine transdermal patch was developed utilizing a solvent casting technique.

Methods: The characteristics of a transdermal patch, including patch weight, folding endurance, patch thickness, surface morphology, tensile strength, swelling rate, surface pH, in vitro release studies, water retention rate, uniformity of drug content, and ex-vivo permeation studies, were determined.

Results: In vitro drug release studies unequivocally demonstrated that drug release controlled polymer interactions. There was no apparent lag period before the drug release rate started to decline. The developed patch showed 70 ± 1.18 % of prolongation of drug release within 24 hours. The result of the penetration studies demonstrated that 61 ± 2.52% of rotigotine permeated through the epidermal barrier within 24 h.

Conclusion: The developed transdermal patch comprising rotigotine was evidently placed on the dermis layer, and an appropriate dose was delivered into circulation for a longer time based on the aforementioned factors. The findings of this study illustrate the effective approach of transdermal patches to treat Parkinson's disease.

查看原文本刊更多论文

利用透皮贴剂智能给药罗替戈汀，成功治疗帕金森病。

背景：非麦角多巴胺激动剂（NEDA）罗替戈汀被设计为一种新型透皮给药系统：目的：为了保持药物含量的最佳均一性，利用溶剂浇铸技术开发了一种非麦角多巴胺激动剂（NEDA）罗替戈汀透皮贴片：方法：确定透皮贴片的特性，包括贴片重量、耐折度、贴片厚度、表面形态、拉伸强度、膨胀率、表面 pH 值、体外释放研究、保水率、药物含量均匀性和体内外渗透研究：体外药物释放研究明确表明，药物释放受聚合物相互作用的控制。在药物释放率开始下降之前没有明显的滞后期。所开发的贴片在 24 小时内的药物释放时间延长了 70 ± 1.18%。渗透研究结果表明，61 ± 2.52% 的罗替戈汀在 24 小时内透过表皮屏障：结论：基于上述因素，所开发的含罗替戈汀的透皮贴片明显贴于真皮层，并能在较长时间内将适当剂量的药物输送到血液循环中。本研究结果表明，透皮贴剂是治疗帕金森病的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Central nervous system agents in medicinal chemistry

自引率

0.00%

发文量